Aug 2026· American Journal of Medicine· 0 citations· 31 references
Medicine
TL;DR
High LDL-C levels were associated with increased cardiovascular risk in patients with chronic kidney disease but not in patients with end-stage kidney disease after multivariable adjustment, suggesting stage-specific LDL-C targets are needed to optimize cardiovascular risk management in chronic kidney disease.
Abstract
Background
Lipid management differs between patients with chronic kidney disease and other high-risk populations due to less established association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular events and unclear benefits of statin in chronic kidney disease. We aimed to investigate the association between LDL-C levels and cardiovascular risk stratified by kidney function.
Methods
Using Korean National Health Insurance Service database, we conducted a population-based cohort study including 4,418,485 patients without cardiovascular disease history who underwent health screenings in 2012. Participants were categorized into three groups based on kidney function and five groups according to LDL-C levels. The primary outcomes were myocardial infarction, ischemic stroke, coronary revascularization, and cardiovascular death.
Results
Over a mean follow-up of 10.1 years, 80,642 myocardial infarctions, 88,833 strokes, 60,884 coronary revascularizations, and 25,256 cardiovascular deaths occurred. In the chronic kidney disease group, LDL-C levels ≥100 mg/dL were significantly associated with increased composite cardiovascular event risk compared with <70 mg/dL; however, this adjusted association was observed in the end-stage kidney disease group. The 5-year absolute risk increased with LDL-C levels and was further intensified by chronic kidney disease stage progression. Different LDL-C thresholds for cardiovascular risk were identified according to chronic kidney disease stage. Subgroup analyses showed that older age, male sex, and the presence of hypertension, diabetes, or proteinuria strengthened the association between LDL-C and cardiovascular events.
Conclusions
High LDL-C levels were associated with increased cardiovascular risk in patients with chronic kidney disease but not in patients with end-stage kidney disease after multivariable adjustment. Stage-specific LDL-C targets are needed to optimize cardiovascular risk management in chronic kidney disease.
In T2DM, LDL-C burden and variability jointly identified patients at greater risk, especially for MI and cardiovascular mortality, especially in younger adults or longer-duration diabetes subgroups.
Dae-Jeong Koo, J. Park, Kyungdo Han et al.· Diabetes, obesity and metabo...· 0 citations
Abstract Background and aims Low-density lipoprotein cholesterol (LDL-C) level is one important modifiable risk factor for cardiovascular diseases. This study aimed to describe the characteristics of primary health care patients with hypertension, coronary artery disease, or diabetes according to their LDL-C levels and...
Petra Valkonen, Ulla Mikkonen, H. Kautiainen et al.· Scandinavian Journal of Prim...· 0 citations
Dyslipidemia is a major contributor to adverse outcomes in patients with coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a comprehensive lipid marker, but its prognostic value in this high-risk populat...
Niuniu Wang, Xue-Jin Chen, Hao-Ran Li et al.· Medicine· 0 citations
BackgroundElevated low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for coronary heart disease, but its role in stroke remains unclear. This study examined the association between LDL-C levels and the risk of cardiovascular disease (CVD) and its subtypes in a large cohort of Japanese worker...
Huan Hu, T. Nakagawa, T. Honda et al.· Journal of Epidemiology· 0 citations
Background Suboptimal cholesterol management in patients with coronary artery disease (CAD) may contribute to future cardiovascular events and increased health care utilization and costs. Objectives The objectives of the study was to assess lipid-lowering medication use and low-density lipoprotein cholesterol (LDL-C) l...
L. Colantonio, Zhi-Xin Wang, Stephen L. Sigal et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.